Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N.

Ann Rheum Dis. 2019 Sep 9. pii: annrheumdis-2019-215933. doi: 10.1136/annrheumdis-2019-215933. [Epub ahead of print]

PMID:
31501138
2.

Architectural Modification of Conformal PEG-Bottlebrush Coatings Minimizes Anti-PEG Antigenicity While Preserving Stealth Properties.

Joh DY, Zimmers Z, Avlani M, Heggestad JT, Aydin HB, Ganson N, Kumar S, Fontes CM, Achar RK, Hershfield MS, Hucknall AM, Chilkoti A.

Adv Healthc Mater. 2019 Apr;8(8):e1801177. doi: 10.1002/adhm.201801177. Epub 2019 Mar 25.

PMID:
30908902
3.

Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.

Moreno A, Pitoc GA, Ganson NJ, Layzer JM, Hershfield MS, Tarantal AF, Sullenger BA.

Cell Chem Biol. 2019 May 16;26(5):634-644.e3. doi: 10.1016/j.chembiol.2019.02.001. Epub 2019 Feb 28.

PMID:
30827937
4.

ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation.

Barzaghi F, Minniti F, Mauro M, Bortoli M, Balter R, Bonetti E, Zaccaron A, Vitale V, Omrani M, Zoccolillo M, Brigida I, Cicalese MP, Degano M, Hershfield MS, Aiuti A, Bondarenko AV, Chinello M, Cesaro S.

Front Immunol. 2019 Jan 14;9:2767. doi: 10.3389/fimmu.2018.02767. eCollection 2018.

5.

Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.

Kohn DB, Hershfield MS, Puck JM, Aiuti A, Blincoe A, Gaspar HB, Notarangelo LD, Grunebaum E.

J Allergy Clin Immunol. 2019 Mar;143(3):852-863. doi: 10.1016/j.jaci.2018.08.024. Epub 2018 Sep 5.

PMID:
30194989
6.

Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2.

Lee PY, Huang Y, Zhou Q, Schnappauf O, Hershfield MS, Li Y, Ganson NJ, Sampaio Moura N, Delmonte OM, Stone SS, Rivkin MJ, Pai SY, Lyons T, Sundel RP, Hsu VW, Notarangelo LD, Aksentijevich I, Nigrovic PA.

J Allergy Clin Immunol. 2018 Oct;142(4):1363-1365.e8. doi: 10.1016/j.jaci.2018.05.038. Epub 2018 Jun 21. No abstract available.

7.

Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout.

Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):427-434. doi: 10.1002/acr.23607.

PMID:
29799677
8.

Hematopoietic Stem Cell Transplantation in ADA2 Deficiency: Early Restoration of ADA2 Enzyme Activity and Disease Relapse upon Drop of Donor Chimerism.

Bucciol G, Delafontaine S, Segers H, Bossuyt X, Hershfield MS, Moens L, Meyts I.

J Clin Immunol. 2017 Nov;37(8):746-750. doi: 10.1007/s10875-017-0449-8. Epub 2017 Oct 10. No abstract available.

PMID:
28993957
9.

Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders.

Hashem H, Kelly SJ, Ganson NJ, Hershfield MS.

Curr Rheumatol Rep. 2017 Oct 5;19(11):70. doi: 10.1007/s11926-017-0699-8. Review.

PMID:
28983775
10.

A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol.

Chang CJ, Chen CH, Chen BM, Su YC, Chen YT, Hershfield MS, Lee MM, Cheng TL, Chen YT, Roffler SR, Wu JY.

Nat Commun. 2017 Sep 12;8(1):522. doi: 10.1038/s41467-017-00622-4.

11.

Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency.

Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ, Ganson NJ, Kfir-Erenfeld S, Weintraub M, Elpeleg O, Berkun Y, Stepensky P.

J Pediatr. 2016 Oct;177:316-320. doi: 10.1016/j.jpeds.2016.06.058. Epub 2016 Aug 8.

PMID:
27514238
12.

Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation.

Hsu AP, West RR, Calvo KR, Cuellar-Rodriguez J, Parta M, Kelly SJ, Ganson NJ, Hershfield MS, Holland SM, Hickstein DD.

J Allergy Clin Immunol. 2016 Aug;138(2):628-630.e2. doi: 10.1016/j.jaci.2016.03.016. Epub 2016 Apr 6. No abstract available.

13.

A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity.

Qi Y, Simakova A, Ganson NJ, Li X, Luginbuhl KM, Özer I, Liu W, Hershfield MS, Matyjaszewski K, Chilkoti A.

Nat Biomed Eng. 2016;1. pii: 0002. doi: 10.1038/s41551-016-0002. Epub 2016 Nov 28.

14.

Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.

Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP, Hershfield MS.

J Allergy Clin Immunol. 2016 May;137(5):1610-1613.e7. doi: 10.1016/j.jaci.2015.10.034. Epub 2015 Dec 11. No abstract available.

15.

A 24-Year Enzyme Replacement Therapy in an Adenosine-deaminase-Deficient Patient.

Tartibi HM, Hershfield MS, Bahna SL.

Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-2169. Epub 2015 Dec 18.

16.

Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency.

Komarow HD, Sokolic R, Hershfield MS, Kohn DB, Young M, Metcalfe DD, Candotti F.

Orphanet J Rare Dis. 2015 Dec 18;10:159. doi: 10.1186/s13023-015-0365-z.

17.

Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.

Baffelli R, Notarangelo LD, Imberti L, Hershfield MS, Serana F, Santisteban I, Bolda F, Porta F, Lanfranchi A.

J Clin Immunol. 2015 Oct;35(7):624-37. doi: 10.1007/s10875-015-0191-z. Epub 2015 Sep 16.

PMID:
26376800
18.

Effects of enzyme replacement therapy on immune function in ADA deficiency patient.

Nakazawa Y, Kawai T, Uchiyama T, Goto F, Watanabe N, Maekawa T, Ishiguro A, Okuyama T, Otsu M, Yamada M, Hershfield MS, Ariga T, Onodera M.

Clin Immunol. 2015 Dec;161(2):391-3. doi: 10.1016/j.clim.2015.06.011. Epub 2015 Jun 27. No abstract available.

PMID:
26122173
19.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Jan;99(1):36-7. doi: 10.1002/cpt.161. Epub 2015 Jul 16.

20.

Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.

Otsu M, Yamada M, Nakajima S, Kida M, Maeyama Y, Hatano N, Toita N, Takezaki S, Okura Y, Kobayashi R, Matsumoto Y, Tatsuzawa O, Tsuchida F, Kato S, Kitagawa M, Mineno J, Hershfield MS, Bali P, Candotti F, Onodera M, Kawamura N, Sakiyama Y, Ariga T.

J Clin Immunol. 2015 May;35(4):384-98. doi: 10.1007/s10875-015-0157-1. Epub 2015 Apr 15.

PMID:
25875699
21.

Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency.

Van Eyck L Jr, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, Frans G, Schaballie H, De Hertogh G, Dooley J, Bossuyt X, Wouters C, Liston A, Meyts I.

J Allergy Clin Immunol. 2015 Jan;135(1):283-7.e5. doi: 10.1016/j.jaci.2014.10.010. Epub 2014 Nov 25. No abstract available.

22.

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.

Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS.

Arthritis Res Ther. 2014 Mar 7;16(2):R63. doi: 10.1186/ar4500.

23.

Early-onset stroke and vasculopathy associated with mutations in ADA2.

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I.

N Engl J Med. 2014 Mar 6;370(10):911-20. doi: 10.1056/NEJMoa1307361. Epub 2014 Feb 19.

24.

Elevated IgE and atopy in patients treated for early-onset ADA-SCID.

Lawrence MG, Barber JS, Sokolic RA, Garabedian EK, Desai AN, O'Brien M, Jones N, Bali P, Hershfield MS, Stone KD, Candotti F, Milner JD.

J Allergy Clin Immunol. 2013 Dec;132(6):1444-6. doi: 10.1016/j.jaci.2013.05.040. Epub 2013 Jul 26. No abstract available.

25.

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT.

Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.

26.

Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Candotti F, Shaw KL, Muul L, Carbonaro D, Sokolic R, Choi C, Schurman SH, Garabedian E, Kesserwan C, Jagadeesh GJ, Fu PY, Gschweng E, Cooper A, Tisdale JF, Weinberg KI, Crooks GM, Kapoor N, Shah A, Abdel-Azim H, Yu XJ, Smogorzewska M, Wayne AS, Rosenblatt HM, Davis CM, Hanson C, Rishi RG, Wang X, Gjertson D, Yang OO, Balamurugan A, Bauer G, Ireland JA, Engel BC, Podsakoff GM, Hershfield MS, Blaese RM, Parkman R, Kohn DB.

Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11.

27.

Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency.

Kanegane H, Taneichi H, Nomura K, Wada T, Yachie A, Imai K, Ariga T, Santisteban I, Hershfield MS, Miyawaki T.

Pediatr Transplant. 2013 Feb;17(1):E29-32. doi: 10.1111/j.1399-3046.2012.01762.x. Epub 2012 Jul 17.

PMID:
22805442
28.

Delayed-onset adenosine deaminase deficiency: strategies for an early diagnosis.

Speckmann C, Neumann C, Borte S, la Marca G, Sass JO, Wiech E, Fisch P, Schwarz K, Buchholz B, Schlesier M, Felgentreff K, Grimbacher B, Santisteban I, Bali P, Hershfield MS, Ehl S.

J Allergy Clin Immunol. 2012 Oct;130(4):991-4. doi: 10.1016/j.jaci.2012.04.004. Epub 2012 May 10. No abstract available.

PMID:
22578972
29.

Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis.

Nakaoka H, Kanegane H, Taneichi H, Miya K, Yang X, Nomura K, Takezaki S, Yamada M, Ohara O, Kamae C, Imai K, Nonoyama S, Wada T, Yachie A, Hershfield MS, Ariga T, Miyawaki T.

Int J Hematol. 2012 Jun;95(6):692-6. doi: 10.1007/s12185-012-1055-4. Epub 2012 Mar 24.

PMID:
22447032
30.

Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency.

Sokolic R, Maric I, Kesserwan C, Garabedian E, Hanson IC, Dodds M, Buckley R, Issekutz AC, Kamani N, Shaw K, Tan B, Bali P, Hershfield MS, Kohn DB, Wayne AS, Candotti F.

Blood. 2011 Sep 8;118(10):2688-94. doi: 10.1182/blood-2011-01-329359. Epub 2011 Jul 1. Erratum in: Blood. 2014 Mar 13;123(11):1767.

31.

ADA-SCID with 'WAZA-ARI' mutations that synergistically abolished ADA protein stability.

Okura Y, Yamada M, Kobayashi I, Santisteban I, Arredondo-Santisteban G, Kato Z, Iguchi A, Yoshida M, Ohara O, Nakagawa N, Imai K, Hershfield MS, Ariga T.

Br J Haematol. 2011 Jun;153(5):675-6. doi: 10.1111/j.1365-2141.2011.08640.x. Epub 2011 Mar 16. No abstract available.

PMID:
21410451
32.

Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation.

Denoble AE, Huffman KM, Stabler TV, Kelly SJ, Hershfield MS, McDaniel GE, Coleman RE, Kraus VB.

Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2088-93. doi: 10.1073/pnas.1012743108. Epub 2011 Jan 18.

33.

Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.

Hershfield MS, Roberts LJ 2nd, Ganson NJ, Kelly SJ, Santisteban I, Scarlett E, Jaggers D, Sundy JS.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14351-6. doi: 10.1073/pnas.1001072107. Epub 2010 Jul 26.

34.

A novel mutation in purine nucleoside phosphorylase in a child with normal uric acid levels.

Al-Saud B, Alsmadi O, Al-Muhsen S, Al-Ghonaium A, Al-Dhekri H, Arnaout R, Hershfield MS, Al-Mousa H.

Clin Biochem. 2009 Nov;42(16-17):1725-7. doi: 10.1016/j.clinbiochem.2009.08.017. Epub 2009 Sep 3.

PMID:
19733163
35.

Purine nucleoside phosphorylase deficiency with fatal course in two sisters.

Aytekin C, Dogu F, Tanir G, Guloglu D, Santisteban I, Hershfield MS, Ikinciogullari A.

Eur J Pediatr. 2010 Mar;169(3):311-4. doi: 10.1007/s00431-009-1029-6. Epub 2009 Aug 6.

PMID:
19657670
36.

How I treat ADA deficiency.

Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD.

Blood. 2009 Oct 22;114(17):3524-32. doi: 10.1182/blood-2009-06-189209. Epub 2009 Jul 28. Review.

37.

Reassessing serum urate targets in the management of refractory gout: can you go too low?

Hershfield MS.

Curr Opin Rheumatol. 2009 Mar;21(2):138-42. doi: 10.1097/BOR.0b013e3283257b83. Review.

38.

Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.

Liu P, Santisteban I, Burroughs LM, Ochs HD, Torgerson TR, Hershfield MS, Rawlings DJ, Scharenberg AM.

Clin Immunol. 2009 Feb;130(2):162-74. doi: 10.1016/j.clim.2008.08.026. Epub 2008 Oct 25.

39.

In memoriam: J. Edwin Seegmiller, M.D. (1920-2006).

Becker MA, Friedmann T, Raivio KO, Hershfield MS, Nuki G.

Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):554-6. doi: 10.1080/15257770802135638. No abstract available.

PMID:
18600502
40.

An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication.

Aytekin C, Yuksek M, Dogu F, Yagmurlu A, Yildiran A, Fitoz S, Kologlu M, Babacan E, Hershfield MS, Ikinciogullari A.

Pediatr Transplant. 2008 Jun;12(4):479-82. doi: 10.1111/j.1399-3046.2007.00890.x. Epub 2008 Jan 14.

PMID:
18208442
41.

A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.

Bax BE, Bain MD, Fairbanks LD, Webster AD, Ind PW, Hershfield MS, Chalmers RA.

Eur J Haematol. 2007 Oct;79(4):338-48. Epub 2007 Aug 3.

PMID:
17680812
42.

Uricase and other novel agents for the management of patients with treatment-failure gout.

Sundy JS, Hershfield MS.

Curr Rheumatol Rep. 2007 Jun;9(3):258-64. Review.

PMID:
17531181
43.

Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS.

Arthritis Rheum. 2007 Mar;56(3):1021-8. Erratum in: Arthritis Rheum. 2007 Apr;56(4):1370.

44.

Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications.

Hönig M, Albert MH, Schulz A, Sparber-Sauer M, Schütz C, Belohradsky B, Güngör T, Rojewski MT, Bode H, Pannicke U, Lippold D, Schwarz K, Debatin KM, Hershfield MS, Friedrich W.

Blood. 2007 Apr 15;109(8):3595-602. Epub 2006 Dec 21.

45.

Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report.

Engel BC, Podsakoff GM, Ireland JL, Smogorzewska EM, Carbonaro DA, Wilson K, Shah A, Kapoor N, Sweeney M, Borchert M, Crooks GM, Weinberg KI, Parkman R, Rosenblatt HM, Wu SQ, Hershfield MS, Candotti F, Kohn DB.

Blood. 2007 Jan 15;109(2):503-6. Epub 2006 Sep 14.

47.

Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.

Kaufman DA, Hershfield MS, Bocchini JA, Moissidis IJ, Jeroudi M, Bahna SL.

Pediatrics. 2005 Dec;116(6):e876-9. Epub 2005 Nov 1.

PMID:
16263974
48.

Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, Parkman R, Weinberg K, Kohn DB.

Clin Immunol. 2005 Nov;117(2):133-43. Epub 2005 Aug 22.

PMID:
16112907
49.

CD28 costimulatory signal induces protein arginine methylation in T cells.

Blanchet F, Cardona A, Letimier FA, Hershfield MS, Acuto O.

J Exp Med. 2005 Aug 1;202(3):371-7.

50.

polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency.

Lainka E, Hershfield MS, Santisteban I, Bali P, Seibt A, Neubert J, Friedrich W, Niehues T.

Clin Diagn Lab Immunol. 2005 Jul;12(7):861-6.

Supplemental Content

Loading ...
Support Center